Search results
Why Novartis Stock Topped the Market on Tuesday
Motley Fool via Yahoo Finance· 5 days agoScooting past analyst estimates for its latest quarter gave Novartis (NYSE: NVS) a lift on Tuesday. Investors like what they heard about the global...
Novartis raises full-year sales and profit guidance after strong Q1
Proactive Investors· 5 days agoNovartis AG (ADR) (NYSE:NVS) has raised its full-year revenue and profit guidance following a strong...
Novartis hikes full-year guidance as Q1 results exceed estimates, shares pop By Investing.com
Investing.com· 6 days agoNovartis hikes full-year guidance as Q1 results exceed estimates, shares pop
Earnings call: Novartis reports strong Q1 with upgraded full-year guidance By Investing.com
Investing.com· 4 days agoNovartis AG (SIX:NOVN) has delivered a robust financial performance in the first quarter of 2024,...
Novartis wins pediatric indication for Lutathera for rare cancer
Seeking Alpha· 5 days agoNovartis' Lutathera has received FDA approval for children aged 12 and above with certain types of...
Novartis (NVS) Q1 Earnings, Sales Beat, Guidance Raised
Zacks via Yahoo Finance· 5 days agoSwiss pharma giant Novartis AG NVS reported better-than-expected results for the first quarter of...
Cwm LLC Sells 1,204 Shares of Novartis AG (NYSE:NVS)
ETF DAILY NEWS· 6 days agoCwm LLC lessened its position in Novartis AG (NYSE:NVS – Free Report) by 1.4% during the fourth quarter, according to the company in its most recent filing with the Securities ...
Novartis raises guidance after beating Q1 expectations By Reuters
Investing.com· 6 days agoFRANKFURT (Reuters) -Swiss drugmaker Novartis (LON:0QLR) raised its full-year guidance on wider use...
Novartis AG (NYSE:NVS) Expected to Post Q3 2025 Earnings of $1.98 Per Share
ETF DAILY NEWS· 5 days agoNovartis AG (NYSE:NVS – Free Report) – Analysts at Zacks Research cut their Q3 2025 earnings per share estimates for shares of Novartis in a note issued ...
Novartis Raises Guidance on Profit, Sales Growth
The Wall Street Journal· 6 days agoNovartis lifted its full-year guidance after first-quarter profit and sales rose and beat consensus expectations, boosted by strong sales of key drugs.